Lundbeck's bets on new drug launches off to a good start - CEO

Danish drug maker Lundbeck is making solid progress with new product launches, a key focus area as it aims to double its revenue base by 2020, Chief Executive Ulf Wiinberg said on Monday. The firm has bet heavily on new products with particular emphasis on drugs like its novel antidepressant Brintellix, alcohol dependence treatment Selincro, multiple psychiatric diseases drug Brexpiprazole and schizophrenia treatment Abilify Maintena. Brintellix, which was approved in the United States in September and is co-marketed with Takeda Pharmaceutical, is one of its key products, as the patents of its existing antidepressant expires. "We believe that treatment with Brintellix indicates meaningful differentiation to other compounds out there," Torsten Meldgaard Madsen, a director of the Brintellix science team said.



via Health News Headlines - Yahoo! News http://news.yahoo.com/lundbecks-bets-drug-launches-off-good-start-ceo-155255035--finance.html